Why Inadequate Response Is So Common

The STAR*D study — the largest and most rigorous treatment study of major depression ever conducted — found that only about one-third of patients achieved remission with their first antidepressant trial. After a second trial, cumulative remission rates reached approximately 50%. These numbers are clinically important: the majority of people with major depression do not achieve remission with their first treatment attempt, and many require multiple adjustments before finding an adequate response.

This is not because antidepressants do not work. It is because depression is biologically heterogeneous — not a single disease with a single mechanism but a clinical syndrome that reflects multiple different neurobiological processes, only some of which are addressed by any given medication. A patient whose depression is primarily driven by inflammatory mechanisms may not respond adequately to serotonergic antidepressants; one whose depression involves primarily noradrenergic dysfunction may show better response to SNRIs or bupropion than to SSRIs.

Several clinical factors predict reduced response to initial antidepressant treatment: chronicity of the current episode (longer duration predicts harder-to-treat depression); co-occurring anxiety (anxiety complicates and extends the treatment course); sub-threshold bipolar features (unrecognized bipolar disorder is treated ineffectively with antidepressant monotherapy); medical comorbidities; chronic pain; substance use; and inadequate dose or duration of the initial trial. Many inadequate treatment responses reflect one of these identifiable and addressable factors.

What Adequate Treatment Actually Means

Before concluding that treatment has failed, it is worth ensuring that what was tried actually constitutes an adequate trial. Many apparent treatment failures are actually under-dosed or under-duration trials that were not given the conditions for adequate response.

Adequate dose. SSRIs have dose-response relationships that are often underutilized. Sertraline at 50 mg/day is a starting dose, not a therapeutic dose for most patients — doses of 100–200 mg/day are therapeutic for many. Escitalopram at 10 mg/day may be inadequate for patients who respond only at 20 mg/day. Starting doses are chosen for tolerability; therapeutic doses may require more. If a trial has never been at the upper end of the therapeutic dose range, dose optimization before switching is the appropriate next step.

Adequate duration. Full antidepressant response takes 6–8 weeks at therapeutic dose. Switching medications at four weeks because of inadequate response may be premature — the response may still be developing. If a patient has partial response at four weeks at therapeutic dose, continuing for another two to four weeks before concluding inadequacy is often warranted.

Adequate adherence. Antidepressants that are not taken consistently do not work consistently. If adherence has been imperfect — missed doses, periods of stopping, not reaching therapeutic dose because of side effect concerns — the trial may not reflect the medication’s actual potential. Addressing adherence barriers before switching is important.

Evidence-Based Next Steps

When an adequate trial has genuinely not produced sufficient response, the evidence base supports several approaches that are specifically indicated for inadequate antidepressant response.

Augmentation adds a second agent to the existing antidepressant rather than switching away from it. First-line augmentation strategies with strong evidence include: adding aripiprazole, quetiapine, or brexpiprazole (atypical antipsychotics with FDA approval for adjunctive MDD treatment); adding lithium; adding bupropion to an SSRI (leverages noradrenergic/dopaminergic mechanisms); or adding a T3 thyroid hormone. Augmentation is preferred over switching when there has been partial response to the initial agent — the partial response suggests the mechanism has some effect, and augmentation builds on it.

Switching antidepressants is indicated when there has been no meaningful response to an adequate trial, or when side effects are intolerable. Switching to a different class — from an SSRI to an SNRI or to bupropion — is more likely to produce response than switching within the same class. Pharmacogenomic testing can inform switching decisions by identifying metabolic phenotypes that may explain non-response.

Adding psychotherapy significantly improves response rates in patients with inadequate medication response. CBT combined with antidepressants outperforms medication alone in treatment-resistant depression, and the combination improves long-term outcomes beyond either alone.

SPRAVATO (esketamine) is FDA-approved for treatment-resistant depression defined as inadequate response to two or more adequate antidepressant trials. It works through a glutamatergic mechanism fundamentally different from conventional antidepressants, producing faster onset of effect. ETX Psychiatry is a certified SPRAVATO treatment center in Tyler, TX.

Call (430) 288-5800 or schedule online. We accept Medicare, Aetna, BCBS, Cigna, Optum, UHC, UMR, and Ambetter. 100 Independence Pl, Suite 405, Tyler, TX 75703. Telehealth available.

When to Seek a Second Opinion

If depression has not responded adequately to two or more medication trials, the clinical situation warrants comprehensive reassessment before continuing to cycle through additional medication changes. A second opinion or comprehensive review should examine: whether the diagnosis is correct (unrecognized bipolar disorder, ADHD, PTSD, or other conditions can produce depression-like presentations that do not respond to antidepressant monotherapy); whether all identified contributing factors (sleep disorder, chronic pain, substance use, medical conditions) are being adequately addressed; whether adequate trials have been conducted at appropriate doses and durations; and whether treatment-resistant depression options including SPRAVATO have been discussed.

ETX Psychiatry provides comprehensive depression evaluation for patients whose current treatment is not producing adequate response. We take treatment history thoroughly and develop individualized plans based on the specific clinical picture rather than continuing the same unsuccessful approaches. For patients who qualify, SPRAVATO provides an evidence-based option that many patients have not been offered. ETX Psychiatry serves Tyler, Longview, Lufkin, Nacogdoches, and East Texas patients via telehealth. Call (430) 288-5800.